BPG is committed to discovery and dissemination of knowledge
Articles in Press
12/4/2025 8:05:20 AM | Browse: 144 | Download: 0
| Category |
Biochemistry & Molecular Biology |
| Manuscript Type |
Case Control Study |
| Article Title |
Altered endocannabinoid system gene expression in inflammatory bowel disease mucosa: New perspectives in inflammatory bowel disease management
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Iulia Andreea Pelisenco, Alessandro Salvi, Giuseppina De Petro, Ioana Andreea Musat, Teodora Ecaterina Manuc, Cristian George Tieranu, Gabriel Becheanu, Elena Milanesi and Maria Dobre |
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| Romanian Ministry of Research, Innovation and Digitization |
PN 23.16.02.04 |
|
| Corresponding Author |
Elena Milanesi, Assistant Professor, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Eroii Sanitari Bvd., no. 8, sector 5, Bucharest 050474, Romania. elena.k.milanesi@gmail.com |
| Key Words |
Endocannabinoid system; Inflammatory bowel disease; Crohn’s disease; Ulcerative colitis; Gene expression |
| Core Tip |
The anti-inflammatory benefits of cannabinoids could serve as a potential new treatment for patients suffering from inflammatory bowel disease (IBD). In this study, we analyzed the expression level of 10 genes belonging to the endocannabinoid system in colonic mucosa from IBD patients vs controls. CNR2, FAAH, GPR18, GPR55, PPARG, and TRPV1 genes were dysregulated in the entire IBD cohort. Stratifying patients into Crohn's disease and ulcerative colitis subgroups, we found that the same 6 genes were dysregulated in at least one comparison. Further analysis of the endocannabinoid system could bridge the gap between preclinical findings and its role in gastrointestinal diseases. |
| Citation |
Pelisenco IA, Salvi A, De Petro G, Musat IA, Manuc TE, Tieranu CG, Becheanu G, Milanesi E, Dobre M. Altered endocannabinoid system gene expression in inflammatory bowel disease mucosa: New perspectives in inflammatory bowel disease management. World J Gastrointest Endosc 2026; 18(2): 113576 |
 |
Received |
|
2025-08-29 05:13 |
|
Peer-Review Started |
|
2025-08-29 05:13 |
|
First Decision by Editorial Office Director |
|
2025-09-12 06:43 |
|
Return for Revision |
|
2025-09-12 06:43 |
|
Revised |
|
2025-09-24 14:48 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-12-04 02:35 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-12-04 08:05 |
|
Articles in Press |
|
2025-12-04 08:05 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-01-30 01:04 |
| ISSN |
1948-5190 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
